PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration ...

The US Food and Drug Administration (FDA) has expanded the indication for the more rapid-acting version of insulin aspart (Fiasp, Novo Nordisk) for use in insulin pumps. Injectable and intravenous ...

Novo Nordisk announced that the FDA has approved its insulin aspart injection Fiasp, which can rapidly improve glycemic control at mealtimes for patients with type 1 and type 2 diabetes. Novo Nordisk ...

Both medications received approval from the FDA in 2017. Ozempic (semaglutide injection) and Fiasp (insulin aspart injection), two recently-approved diabetes treatments, are now available in U.S.

The FDA expanded the use of Fiasp, a fast-acting insulin aspart injection, in children as young as 2 years to treat diabetes. First approved for adults in 2017, Novo Nordisk said it is the only ...

BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- New data presented today at the 55 th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with ...

The approval was based on data from an active-controlled, treat-to-target trial (Onset7) that included 777 pediatric patients (aged 2 to 17 years) with type 1 diabetes. The Food and Drug ...

Fiasp is formulated with niacinamide which helps increase the speed of the initial insulin absorption. The Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection; Novo Nordisk ...

Novo Nordisk has received the Food and Drug Administration’s clearance for Fiasp (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in ...

BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- New data presented today at the 55 th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with ...

New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not ...